Medgenics, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference in New York
03 September 2009 - 7:41PM
Business Wire
Medgenics (AIM:MEDU)(AIM:MEDG). today announced that Dr. Andrew
Pearlman, President and Chief Executive Officer, will present at
the Rodman & Renshaw Conference on Thursday, September 10th
from 5:20 to 5:45 in the Garrison Salon (5th Floor) at the New York
Palace Hotel.
Dr. Andrew Pearlman, will also be available for one-on-one
meetings with analysts and investors on Thursday, September
10th.
Medgenics recently announced the unparalleled attainment of 11+
months of sustained treatment in anemic patients receiving a single
administration of the Company’s EPODURE tissue based Biopump
sustained protein therapy. Management will discuss these and other
results from its current Phase I/II safety and efficacy trial of
the EPODURE Biopump for providing sustained treatment of anemia in
patients with chronic kidney disease, and the Company’s long-term
growth strategy.
ABOUT MEDGENICS:
Medgenics, Inc. is a clinical-stage biopharmaceutical company
developing its unique tissue-based Biopump platform technology to
provide sustained-action protein therapy for the treatment of a
range of chronic diseases.
The Biopump is a toothpick sized sliver of the patient’s own
dermal tissue obtained under local anesthetic, that has been
processed within 2 weeks to become a unit producing a selected
protein for a specific clinical application. Injected under the
skin, the Biopump produces and delivers the therapeutic protein to
the patient for several months.
Medgenics currently has two products in development based on
this technology:
- EPODURE – producing
erythropoietin (EPO) to treat anemia
- INFRADURE – producing
interferon-alpha (IFN-a) to treat Hepatitis-C
The Company’s ongoing Phase I/II clinical trial for EPODURE in
anemic patients continues to demonstrate proof of concept of the
Biopump. Designed to produce and deliver a therapeutic dose of EPO
steadily for up to six months or more, EPODURE Biopumps are already
maintaining effective anemia treatment for more than 10 months in
earliest patients in the ongoing study, even with the low dose
administered.
Medgenics intends to develop its innovative products and bring
them to market via multiple strategic partnerships with major
pharmaceutical and/or medical device companies, starting with
EPODURE and INFRADURE.
Medgenics plans to raise the requisite funds during 2009/10 to
commence a Phase I/II trial of INFRADURE in Hepatitis-C patients in
Israel during 2010. The Company hopes that partnering discussions
will lead to collaboration also in the next stage of EPODURE
development, likely to be a Phase IIb multicenter study in anemic
patients.
Beyond these, Medgenics plans to develop and/or out-license a
pipeline of future Biopump products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach
US $87 billion by 2010. Other potential areas include multiple
sclerosis (interferon-β), hemophilia (Factor VIII), pediatric
growth hormone deficiency (human growth hormone) and diabetes
(insulin).
Founded in 2000, Medgenics is a US-incorporated company with
major operations in Misgav, Israel. Medgenics was admitted to the
London AIM in December 2007 (AIM: MEDG and AIM: MEDU).
www.medgenics.com
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include
all statements other than statements of historical fact, including
(without limitation) those regarding the Company’s financial
position, business strategy, plans and objectives of management for
future operations. These statements relate to future events,
prospects, developments and strategies. Forward-looking statements
are sometimes identified by their use of the terms and phrases such
as “estimate,” “project,” “intend,” “forecast,” “anticipate,”
“plan,” “planning, “expect,” “believe,” “will,” “will likely,”
“should,” “could,” “would,” “may” or the negative of such terms and
other comparable terminology. All such forward-looking statements
are based on current expectations and are subject to risks and
uncertainties. Should any of these risks or uncertainties
materialize, or should any of the Company’s assumptions prove
incorrect, actual results may differ materially from those included
within these forward-looking statements. Accordingly, no undue
reliance should be placed on these forward-looking statements,
which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained herein to
reflect any change in the Company’s expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. As a result of these factors,
the events described in the forward-looking statements contained in
this release may not occur.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024